FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Crown Holdings Q1: Delivers Revenue Beat With Strong Beverage Shipment Growth

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

CCK delivered solid Q1 2026 results, with net sales of $3,259M (+12.9% Y/Y), beating consensus by $224M, due to 5% global beverage shipment growth and successful pass-through of $234M in higher material costs. Adjusted EPS of $1.86 (+11.4% Y/Y) exceeded consensus estimates of $1.75, though reported EPS declined to $1.56 from $1.65 due to debt extinguishment charges. North American shipments advanced 1% despite a slow start to the year, with strong March performance helping overcome early quarterly weakness. The company demonstrated effective cost recovery capabilities amid persistent inflationary pressures, though margin pressures in key operating segments tempered overall profitability gains. We believe the successful material cost pass-through validates CCK's defensive pricing model and contractual protections, while sustained volume growth across key global markets supports our positive outlook for continued operational momentum and market share expansion.

Related Articles

Asia

Telix Says Marketing Authorization Application for Glioma Imaging Candidate Accepted for Review in Europe; Shares Up 3%

Telix Pharmaceuticals (ASX:TLX) said Friday its marketing authorization application filed in Europe for TLX101-Px, its glioma imaging candidate, has been validated and accepted for review, moving into a 210-day active assessment phase.In a statement, the company said it is seeking a broad clinical label, reflective of current clinical practice guidelines, with national marketing authorizations expected to follow shortly after a positive outcome at day 210.The company said it aims to expand patient access to advanced imaging that can distinguish progressive or recurrent glioma from treatment-related changes in both adults and children, with potential for additional future indications.TLX101-Px is also being developed as a patient selection and response assessment tool for Telix's glioblastoma therapy candidate TLX101-Tx, which has been granted orphan drug designation in Europe and the US, per the statement.The phase 3 IPAX-BrIGHT trial of TLX101-Tx in patients with recurrent glioblastoma has started patient dosing internationally and is launching in multiple European countries, the company said.Telix Pharmaceuticals' shares were up 3% in recent Friday trade.

$ASX:TLX
Asia

Zozo's Profit Climbs 6% in Fiscal Year 2025

Zozo's (TYO:3092) profit attributable to owners of the parent rose 5.7% to 47.93 billion yen for the fiscal year 2025 from 45.35 billion yen a year earlier.The shopping mall operator's basic earnings per share increased to 54.11 yen from 50.90 yen a year ago, according to a Tokyo bourse filing on Thursday.Net sales climbed 7.2% to 228.37 billion yen for the full year ended March 31 from 213.13 billion yen in the prior year.The company declared a year-end dividend of 20 yen per share, payable from June 11.For the fiscal year 2026, the company expects attributable profit of 49.7 billion yen, EPS of 56.20 yen, and net sales of 241.9 billion yen.Zozo plans to pay interim and year-end dividends of 20 yen per share each for the year, which is higher than the amount in the year-ago period.

$TYO:3092
Asia

EML Payments Says Regulators Extend Date for Implementation of Required Guarantee Structure

EML Payments (ASX:EML) said the Australian Prudential Regulation Authority (APRA) and Reserve Bank of Australia (RBA) agreed to extend the date for implementation of the required authorized deposit-taking institution guarantee structure, subject to EML Payment Solutions showing "satisfactory progress" towards obtaining the guarantee via periodic reporting, according to a Friday Australian bourse filing.EML Payment Solutions is engaging with several domestic and international financial institutions, as well as legal advisors and trustee service providers, to design the required guarantee structure.The regulators had earlier said that they require the firm to obtain a guarantee from an authorized deposit-taking institution in respect of stored value liabilities for certain EML Payment Solutions programs by Thursday.

$ASX:EML